BioSpace News Archive

Selexis SA today announced that the Swiss Biotech Association (SBA) has named Selexis to an esteemed group of five Swiss Biotech Success Stories, as determined by a jury of industry experts, based upon the company’s contributions to the biotechnology industry in Switzerland.

Move Reflects Focus on Advancing Several Intranasal Vaccines to Human Studies

athenahealth, Inc. (NASDAQ: ATHN), a leading provider of network-enabled services for hospital and ambulatory customers nationwide, today confirmed that it has received an unsolicited proposal from Elliott Management to acquire the Company for $160 per share in cash.

YUNTONE CAPITAL CORP. (“Yuntone”) (TSX-V: YTC.H) is pleased to announce that it has entered into a business combination agreement dated May 3, 2018 (the “Definitive Agreement”) with GrowX Global Corp. (“GrowX”) and 1160015 B.C. Ltd. (“Subco”), a wholly owned subsidiary of Yuntone, whereby Yuntone will acquire all of the issued and outstanding shares of GrowX (the “Transaction”

AMO Pharma Limited (“AMO Pharma”), a privately held biopharmaceutical company focusing on rare, debilitating childhood onset neurogenetic disorders with limited or no treatment options, today announced initiation of patient recruitment in an interventional study of AMO-01, the company’s investigational Ras-ERK pathway inhibitor, in the treatment of Phelan-McDermid syndrome.

Today, the U.S. Food and Drug Administration permitted marketing of Hemospray, a new device used to help control certain types of bleeding in the gastrointestinal (GI) tract.

Luminex Corporation (Nasdaq:LMNX) today announced financial results for the first quarter of 2018.

Pharmaceutical veteran to lead Cumberland’s Hospital Sales Force

-- Introduced XmAb® IL15 Bispecific Antibody Platform and Presented Preclinical Data on XmAb®24306 at American Association for Cancer Research (AACR) Annual Meeting -- - Completed Public Offering, Raising $245.5M and Extending Cash Runway into 2023 - -- Expect to Initiate Phase 3 Trial of XmAb®5871 in IgG4-Related Disease (IgG4-RD) and to Announce Initial Clinical Data from Two Ongoing Clinical Trials in 2H18 -- - Management to Host Conference Call at 4:30 pm ET today -

Agilent Technologies Inc. (NYSE: A) today announced that it has completed the acquisition of Lasergen, Inc. (Lasergen), an emerging biotechnology company focused on research and development of innovative technologies for DNA sequencing.